Insider Selling: Hinge Health (NYSE:HNGE) Major Shareholder Sells $29,036,250.00 in Stock

Hinge Health Inc. (NYSE:HNGE) major shareholder Bessemer Venture Partners L. sold 725,000 shares of the business’s stock in a transaction dated Tuesday, November 18th. The shares were sold at an average price of $40.05, for a total transaction of $29,036,250.00. Following the completion of the sale, the insider directly owned 3,383,707 shares of the company’s stock, valued at approximately $135,517,465.35. The trade was a 17.65% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Hinge Health Price Performance

HNGE stock traded up $1.23 during trading on Thursday, reaching $45.33. 2,821,713 shares of the company were exchanged, compared to its average volume of 1,175,021. The business’s 50-day moving average is $49.92. Hinge Health Inc. has a twelve month low of $33.42 and a twelve month high of $62.18.

Hinge Health (NYSE:HNGE) last released its earnings results on Tuesday, November 4th. The company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.20) by $0.18. The firm had revenue of $154.21 million during the quarter, compared to analyst estimates of $142.44 million. The business’s revenue for the quarter was up 53.3% compared to the same quarter last year. Hinge Health has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS.

Hinge Health declared that its board has approved a stock buyback program on Wednesday, November 12th that allows the company to repurchase $250.00 million in shares. This repurchase authorization allows the company to purchase up to 7.2% of its shares through open market purchases. Shares repurchase programs are often an indication that the company’s management believes its shares are undervalued.

Hedge Funds Weigh In On Hinge Health

Several hedge funds have recently modified their holdings of HNGE. CHURCHILL MANAGEMENT Corp purchased a new position in Hinge Health in the second quarter worth about $828,000. FNY Investment Advisers LLC bought a new position in Hinge Health during the 2nd quarter worth about $310,000. Strategic Blueprint LLC purchased a new position in shares of Hinge Health in the 2nd quarter valued at $346,000. Emerald Advisers LLC acquired a new stake in Hinge Health in the second quarter valued at approximately $108,000. Finally, Mark Sheptoff Financial Planning LLC acquired a new stake in Hinge Health in the second quarter worth about $114,000.

Analyst Ratings Changes

A number of brokerages have recently commented on HNGE. Canaccord Genuity Group increased their price target on shares of Hinge Health from $61.00 to $65.00 and gave the stock a “buy” rating in a report on Wednesday, November 5th. Baird R W raised Hinge Health to a “hold” rating in a research note on Friday, September 5th. Piper Sandler reiterated an “overweight” rating and issued a $71.00 price objective (up from $70.00) on shares of Hinge Health in a research report on Wednesday, November 5th. JMP Securities lifted their price objective on Hinge Health from $58.00 to $65.00 and gave the company a “market outperform” rating in a research report on Wednesday, August 6th. Finally, Bank of America raised their price objective on Hinge Health from $42.00 to $64.00 and gave the company a “buy” rating in a research report on Wednesday, August 6th. One analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $59.93.

About Hinge Health

Our vision is to build a new health system that transforms outcomes, experience and costs by using technology to scale and automate the delivery of care. Hinge Health leverages software, including AI, to largely automate care for joint and muscle health, delivering an outstanding member experience, improved member outcomes, and cost reductions for our clients.